The Beneficial Effects of Mesenchymal Stem Cells in Acute Kidney Injury:
A Narrative Review

Yuxiang      Liu; Jibin      Han; Jingai      Fang; Rongshan      Li

doi:10.2174/1574888X18666230206115046

Abstract

Background: Acute kidney injury (AKI) is a multifaced disease characterized by a rapid decline in renal function. However, with growing insight into the pathophysiologic mechanisms of AKI, currently available interventions for AKI are merely supportive. Thus, novel therapies are urgently needed to improve the outcomes of patients with AKI. This narrative review aims to explore enhancing the beneficial effects of Mesenchymal Stem Cells(MSCs) in AKI.

Methods: The authors examined all studies regarding the role of MSCs in AKI. And the authors undertook a structured search of bibliographic databases for peer-reviewed research literature using a focused review question. The most relevant and up-to-date research was included.

Results and Discussion: Based on encouraging preclinical results, stem cell therapy has been widely explored over the last decade. Among the various stem cell types investigated, mesenchymal stem cells are being intensely investigated by virtue of their numerous strengths, such as easy derivation, undemanding cell culture conditions, anti-apoptosis, immunomodulation, and anti-inflammation effects. Mounting evidence suggests that MSCs hold great potential in accelerating kidney repair following AKI in various preclinical models. Unfortunately, low engrafting efficiency and poor survival rate of injected MSCs in the injured renal tissue are major obstacles MSCs clinical application faces.

Conclusion: Various strategies, including genetic manipulation, mimicking the cellular microenvironment with different culture conditions, optimizing MSCs preparation and administration schedule, and screening patients who may more like benefit from MSCs therapy, have been developed to enhance the therapeutic potential of MSCs in AKI.

Keywords: Acute kidney injury (AKI), mesenchymal stem cells (MSCs), optimization of treatment, anti-apoptosis, genetic manipulation, renal tissue.

« Previous Next »

Graphical Abstract

[1]
Ronco C, Bellomo R, Kellum JA. Acute kidney injury. Lancet  2019; 394(10212): 1949-64.
 [http://dx.doi.org/10.1016/S0140-6736(19)32563-2] [PMID: 31777389]

[2]
Liangos O, Wald R, O’Bell JW, Price L, Pereira BJ, Jaber BL. Epidemiology and outcomes of acute renal failure in hospitalized patients: A national survey. Clin J Am Soc Nephrol  2006; 1(1): 43-51.
 [http://dx.doi.org/10.2215/CJN.00220605] [PMID: 17699189]

[3]
Hoste EAJ, Bagshaw SM, Bellomo R, et al. Epidemiology of acute kidney injury in critically ill patients: The multinational AKI-EPI study. Intensive Care Med  2015; 41(8): 1411-23.
 [http://dx.doi.org/10.1007/s00134-015-3934-7] [PMID: 26162677]

[4]
Forni LG, Darmon M, Ostermann M, et al. Renal recovery after acute kidney injury. Intensive Care Med  2017; 43(6): 855-66.
 [http://dx.doi.org/10.1007/s00134-017-4809-x] [PMID: 28466146]

[5]
Hoste EAJ, Kellum JA, Selby NM, et al. Global epidemiology and outcomes of acute kidney injury. Nat Rev Nephrol  2018; 14(10): 607-25.
 [http://dx.doi.org/10.1038/s41581-018-0052-0] [PMID: 30135570]

[6]
Lameire NH, Bagga A, Cruz D, et al. Acute kidney injury: An increasing global concern. Lancet  2013; 382(9887): 170-9.
 [http://dx.doi.org/10.1016/S0140-6736(13)60647-9] [PMID: 23727171]

[7]
Liu D, Cheng F, Pan S, Liu Z. Stem cells: A potential treatment option for kidney diseases. Stem Cell Res Ther  2020; 11(1): 249.
 [http://dx.doi.org/10.1186/s13287-020-01751-2] [PMID: 32586408]

[8]
de Almeida DC, Donizetti-Oliveira C, Barbosa-Costa P, Origassa CS, Câmara NO. In search of mechanisms associated with mesenchymal stem cell-based therapies for acute kidney injury. Clin Biochem Rev  2013; 34(3): 131-44.
 [PMID: 24353358]

[9]
Tögel F, Hu Z, Weiss K, Isaac J, Lange C, Westenfelder C. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation-independent mechanisms. Am J Physiol Renal Physiol  2005; 289(1): F31-42.
 [http://dx.doi.org/10.1152/ajprenal.00007.2005] [PMID: 15713913]

[10]
Phinney DG, Pittenger MF. Concise Review: MSC-derived exosomes for cell-free therapy. Stem Cells  2017; 35(4): 851-8.
 [http://dx.doi.org/10.1002/stem.2575] [PMID: 28294454]

[11]
Aghajani Nargesi A, Lerman LO, Eirin A. Mesenchymal stem cell-derived extracellular vesicles for kidney repair: Current status and looming challenges. Stem Cell Res Ther  2017; 8(1): 273.
 [http://dx.doi.org/10.1186/s13287-017-0727-7] [PMID: 29202871]

[12]
Lange C, Tögel F, Ittrich H, et al. Administered mesenchymal stem cells enhance recovery from ischemia/reperfusion-induced acute renal failure in rats. Kidney Int  2005; 68(4): 1613-7.
 [http://dx.doi.org/10.1111/j.1523-1755.2005.00573.x] [PMID: 16164638]

[13]
Peng X, Xu H, Zhou Y, et al. Human umbilical cord mesenchymal stem cells attenuate cisplatin-induced acute and chronic renal injury. Exp Biol Med  2013; 238(8): 960-70.
 [http://dx.doi.org/10.1177/1477153513497176] [PMID: 23970411]

[14]
Luo C, Zhang F, Zhang L, et al. Mesenchymal stem cells ameliorate sepsis-associated acute kidney injury in mice. Shock  2014; 41(2): 123-9.
 [http://dx.doi.org/10.1097/SHK.0000000000000080] [PMID: 24169208]

[15]
Tögel FE, Westenfelder C. Kidney protection and regeneration following acute injury: Progress through stem cell therapy. Am J Kidney Dis  2012; 60(6): 1012-22.
 [http://dx.doi.org/10.1053/j.ajkd.2012.08.034] [PMID: 23036928]

[16]
Swaminathan M, Stafford-Smith M, Chertow GM, et al. Allogeneic mesenchymal stem cells for treatment of AKI after cardiac surgery. J Am Soc Nephrol  2018; 29(1): 260-7.
 [http://dx.doi.org/10.1681/ASN.2016101150] [PMID: 29038286]

[17]
Nitzsche F, Müller C, Lukomska B, Jolkkonen J, Deten A, Boltze J. Concise Review: MSC adhesion cascade—insights into homing and transendothelial migration. Stem Cells  2017; 35(6): 1446-60.
 [http://dx.doi.org/10.1002/stem.2614] [PMID: 28316123]

[18]
Karp JM, Leng Teo GS. Mesenchymal stem cell homing: The devil is in the details. Cell Stem Cell  2009; 4(3): 206-16.
 [http://dx.doi.org/10.1016/j.stem.2009.02.001] [PMID: 19265660]

[19]
Zhao L, Hu C, Zhang P, Jiang H, Chen J. Novel preconditioning strategies for enhancing the migratory ability of mesenchymal stem cells in acute kidney injury. Stem Cell Res Ther  2018; 9(1): 225.
 [http://dx.doi.org/10.1186/s13287-018-0973-3] [PMID: 30139368]

[20]
Ullah M, Liu DD, Thakor AS. Mesenchymal stromal cell homing: Mechanisms and strategies for improvement. iScience  2019; 15: 421-38.
 [http://dx.doi.org/10.1016/j.isci.2019.05.004] [PMID: 31121468]

[21]
Liu N, Tian J, Cheng J, Zhang J. Migration of CXCR4 gene-modified bone marrow-derived mesenchymal stem cells to the acute injured kidney. J Cell Biochem  2013; 114(12): 2677-89.
 [http://dx.doi.org/10.1002/jcb.24615] [PMID: 23794207]

[22]
Liu N, Patzak A, Zhang J. CXCR4-overexpressing bone marrow-derived mesenchymal stem cells improve repair of acute kidney injury. Am J Physiol Renal Physiol  2013; 305(7): F1064-73.
 [http://dx.doi.org/10.1152/ajprenal.00178.2013] [PMID: 23884141]

[23]
Si X, Liu X, Li J, Wu X. Transforming growth factor-β1 promotes homing of bone marrow mesenchymal stem cells in renal ischemia-reperfusion injury. Int J Clin Exp Pathol  2015; 8(10): 12368-78.
 [PMID: 26722423]

[24]
Liu N, Wang H, Han G, Tian J, Hu W, Zhang J. Alleviation of apoptosis of bone marrow-derived mesenchymal stem cells in the acute injured kidney by heme oxygenase-1 gene modification. Int J Biochem Cell Biol  2015; 69: 85-94.
 [http://dx.doi.org/10.1016/j.biocel.2015.10.007] [PMID: 26456668]

[25]
Liu N, Wang H, Han G, Cheng J, Hu W, Zhang J. Enhanced proliferation and differentiation of HO-1 gene-modified bone marrow-derived mesenchymal stem cells in the acute injured kidney. Int J Mol Med  2018; 42(2): 946-56.
 [http://dx.doi.org/10.3892/ijmm.2018.3670] [PMID: 29749549]

[26]
Zhou S, Qiao Y, Liu Y, et al. Bone marrow derived mesenchymal stem cells pretreated with erythropoietin accelerate the repair of acute kidney injury. Cell Biosci  2020; 10(1): 130.
 [http://dx.doi.org/10.1186/s13578-020-00492-2] [PMID: 33292452]

[27]
Eliopoulos N, Zhao J, Forner K, Birman E, Young YK, Bouchentouf M. Erythropoietin gene-enhanced marrow mesenchymal stromal cells decrease cisplatin-induced kidney injury and improve survival of allogeneic mice. Mol Ther  2011; 19(11): 2072-83.
 [http://dx.doi.org/10.1038/mt.2011.162] [PMID: 21847101]

[28]
Liu N, Han G, Cheng J, Huang J, Tian J. Erythropoietin promotes the repair effect of acute kidney injury by bone-marrow mesenchymal stem cells transplantation. Exp Biol Med (Maywood)  2013; 238(6): 678-86.
 [http://dx.doi.org/10.1177/1535370213489486] [PMID: 23918879]

[29]
Hagiwara M, Shen B, Chao L, Chao J. Kallikrein-modified mesenchymal stem cell implantation provides enhanced protection against acute ischemic kidney injury by inhibiting apoptosis and inflammation. Hum Gene Ther  2008; 19(8): 807-19.
 [http://dx.doi.org/10.1089/hum.2008.016] [PMID: 18554097]

[30]
Mohammadzadeh-Vardin M, Habibi Roudkenar M, Jahanian-Najafabadi A. Adenovirus-mediated over-expression of Nrf2 within mesenchymal Stem Cells (MSCs) protected rats against acute kidney injury. Adv Pharm Bull  2015; 5(2): 201-8.
 [http://dx.doi.org/10.15171/apb.2015.028] [PMID: 26236658]

[31]
Zhaleh F, Amiri F, Mohammadzadeh-Vardin M, et al. Nuclear factor erythroid-2 related factor 2 overexpressed mesenchymal stem cells transplantation, improves renal function, decreases injuries markers and increases repair markers in glycerol-induced Acute kidney injury rats. Iran J Basic Med Sci  2016; 19(3): 323-9.
 [PMID: 27114803]

[32]
Zhang F, Wan X, Cao YZ, Sun D, Cao CC. Klotho gene-modified BMSCs showed elevated antifibrotic effects by inhibiting the Wnt/β-catenin pathway in kidneys after acute injury. Cell Biol Int  2018; 42(12): 1670-9.
 [http://dx.doi.org/10.1002/cbin.11068] [PMID: 30358003]

[33]
Xie LB, Chen X, Chen B, Wang XD, Jiang R, Lu YP. Protective effect of bone marrow mesenchymal stem cells modified with klotho on renal ischemia-reperfusion injury. Ren Fail  2019; 41(1): 175-82.
 [http://dx.doi.org/10.1080/0886022X.2019.1588131] [PMID: 30942135]

[34]
Sahan OB, Gunel-Ozcan A. Hepatocyte growth factor and insulin-like growth Factor-1 based cellular therapies for oxidative stress injury. Curr Stem Cell Res Ther  2021; 16(7): 771-91.
 [http://dx.doi.org/10.2174/1574888X16999201124153753] [PMID: 33238860]

[35]
Chen Y, Qian H, Zhu W, et al. Hepatocyte growth factor modification promotes the amelioration effects of human umbilical cord mesenchymal stem cells on rat acute kidney injury. Stem Cells Dev  2011; 20(1): 103-13.
 [http://dx.doi.org/10.1089/scd.2009.0495] [PMID: 20446811]

[36]
Tögel F, Weiss K, Yang Y, Hu Z, Zhang P, Westenfelder C. Vasculotropic, paracrine actions of infused mesenchymal stem cells are important to the recovery from acute kidney injury. Am J Physiol Renal Physiol  2007; 292(5): F1626-35.
 [http://dx.doi.org/10.1152/ajprenal.00339.2006] [PMID: 17213465]

[37]
Yuan L, Wu MJ, Sun HY, et al. VEGF-modified human embryonic mesenchymal stem cell implantation enhances protection against cisplatin-induced acute kidney injury. Am J Physiol Renal Physiol  2011; 300(1): F207-18.
 [http://dx.doi.org/10.1152/ajprenal.00073.2010] [PMID: 20943766]

[38]
Kamenický P, Mazziotti G, Lombès M, Giustina A, Chanson P. Growth hormone, insulin-like growth factor-1, and the kidney: Pathophysiological and clinical implications. Endocr Rev  2014; 35(2): 234-81.
 [http://dx.doi.org/10.1210/er.2013-1071] [PMID: 24423979]

[39]
Imberti B, Morigi M, Tomasoni S, et al. Insulin-like growth factor-1 sustains stem cell mediated renal repair. J Am Soc Nephrol  2007; 18(11): 2921-8.
 [http://dx.doi.org/10.1681/ASN.2006121318] [PMID: 17942965]

[40]
Liu P, Feng Y, Dong D, et al. Enhanced renoprotective effect of IGF-1 modified human umbilical cord-derived mesenchymal stem cells on gentamicin-induced acute kidney injury. Sci Rep  2016; 6(1): 20287.
 [http://dx.doi.org/10.1038/srep20287] [PMID: 26830766]

[41]
Mishra J, Mori K, Ma Q, et al. Amelioration of ischemic acute renal injury by neutrophil gelatinase-associated lipocalin. J Am Soc Nephrol  2004; 15(12): 3073-82.
 [http://dx.doi.org/10.1097/01.ASN.0000145013.44578.45] [PMID: 15579510]

[42]
Roudkenar MH, Halabian R, Tehrani HA, et al. Lipocalin 2 enhances mesenchymal stem cell-based cell therapy in acute kidney injury rat model. Cytotechnology  2018; 70(1): 103-17.
 [http://dx.doi.org/10.1007/s10616-017-0107-2] [PMID: 28573544]

[43]
Islam D, Huang Y, Fanelli V, et al. Identification and modulation of microenvironment is crucial for effective mesenchymal stromal cell therapy in acute lung injury. Am J Respir Crit Care Med  2019; 199(10): 1214-24.
 [http://dx.doi.org/10.1164/rccm.201802-0356OC] [PMID: 30521764]

[44]
Freytes DO, Kang JW, Marcos-Campos I, Vunjak-Novakovic G. Macrophages modulate the viability and growth of human mesenchymal stem cells. J Cell Biochem  2013; 114(1): 220-9.
 [http://dx.doi.org/10.1002/jcb.24357] [PMID: 22903635]

[45]
Das R, Jahr H, van Osch GJVM, Farrell E. The role of hypoxia in bone marrow-derived mesenchymal stem cells: Considerations for regenerative medicine approaches. Tissue Eng Part B Rev  2010; 16(2): 159-68.
 [http://dx.doi.org/10.1089/ten.teb.2009.0296] [PMID: 19698058]

[46]
Cicione C, Muiños-López E, Hermida-Gómez T, Fuentes-Boquete I, Díaz-Prado S, Blanco FJ. Effects of severe hypoxia on bone marrow mesenchymal stem cells differentiation potential. Stem Cells Int  2013; 2013: 1-11.
 [http://dx.doi.org/10.1155/2013/232896] [PMID: 24082888]

[47]
Ferreira JR, Teixeira GQ, Santos SG, Barbosa MA, Almeida-Porada G, Gonçalves RM. Mesenchymal stromal cell secretome: Influencing therapeutic potential by cellular pre-conditioning. Front Immunol  2018; 9: 2837.
 [http://dx.doi.org/10.3389/fimmu.2018.02837] [PMID: 30564236]

[48]
Hung SC, Pochampally RR, Hsu SC, et al. Short-term exposure of multipotent stromal cells to low oxygen increases their expression of CX3CR1 and CXCR4 and their engraftment in vivo. PLoS One  2007; 2(5): e416.
 [http://dx.doi.org/10.1371/journal.pone.0000416] [PMID: 17476338]

[49]
Palomäki S, Pietilä M, Laitinen S, et al. HIF-1α is upregulated in human mesenchymal stem cells. Stem Cells  2013; 31(9): 1902-9.
 [http://dx.doi.org/10.1002/stem.1435] [PMID: 23744828]

[50]
Yu X, Lu C, Liu H, et al. Hypoxic preconditioning with cobalt of bone marrow mesenchymal stem cells improves cell migration and enhances therapy for treatment of ischemic acute kidney injury. PLoS One  2013; 8(5): e62703.
 [http://dx.doi.org/10.1371/journal.pone.0062703] [PMID: 23671625]

[51]
Zhang W, Liu L, Huo Y, Yang Y, Wang Y. Hypoxia-pretreated human MSCs attenuate acute kidney injury through enhanced angiogenic and antioxidative capacities. BioMed Res Int  2014; 2014: 462472.
 [http://dx.doi.org/10.1155/2014/462472] [PMID: 25133162]

[52]
Ishiuchi N, Nakashima A, Doi S, et al. Hypoxia-preconditioned mesenchymal stem cells prevent renal fibrosis and inflammation in ischemia-reperfusion rats. Stem Cell Res Ther  2020; 11(1): 130.
 [http://dx.doi.org/10.1186/s13287-020-01642-6] [PMID: 32197638]

[53]
Petrenko Y, Syková E, Kubinová Š. The therapeutic potential of three-dimensional multipotent mesenchymal stromal cell spheroids. Stem Cell Res Ther  2017; 8(1): 94.
 [http://dx.doi.org/10.1186/s13287-017-0558-6] [PMID: 28446248]

[54]
Zhao X, Qiu X, Zhang Y, Zhang S, Gu X, Guo H. Three-dimensional aggregates enhance the therapeutic effects of adipose mesenchymal stem cells for ischemia-reperfusion induced kidney injury in rats. Stem Cells Int  2016; 2016: 9062638.
 [http://dx.doi.org/10.1155/2016/9062638] [PMID: 26649053]

[55]
Xu Y, Shi T, Xu A, Zhang L. 3D spheroid culture enhances survival and therapeutic capacities of MSC s injected into ischemic kidney. J Cell Mol Med  2016; 20(7): 1203-13.
 [http://dx.doi.org/10.1111/jcmm.12651] [PMID: 26914637]

[56]
Katsuno T, Ozaki T, Saka Y, et al. Low serum cultured adipose tissue-derived stromal cells ameliorate acute kidney injury in rats. Cell Transplant  2013; 22(2): 287-97.
 [http://dx.doi.org/10.3727/096368912X655019] [PMID: 22963874]

[57]
Valencia J, Blanco B, Yáñez R, et al. Comparative analysis of the immunomodulatory capacities of human bone marrow– and adipose tissue–derived mesenchymal stromal cells from the same donor. Cytotherapy  2016; 18(10): 1297-311.
 [http://dx.doi.org/10.1016/j.jcyt.2016.07.006] [PMID: 27637760]

[58]
Ketterl N, Brachtl G, Schuh C, et al. A robust potency assay highlights significant donor variation of human mesenchymal stem/progenitor cell immune modulatory capacity and extended radio-resistance. Stem Cell Res Ther  2015; 6(1): 236.
 [http://dx.doi.org/10.1186/s13287-015-0233-8] [PMID: 26620155]

[59]
Bloor AJC, Patel A, Griffin JE, et al. Production, safety and efficacy of iPSC-derived mesenchymal stromal cells in acute steroid-resistant graft versus host disease: a phase I, multicenter, open-label, dose-escalation study. Nat Med  2020; 26(11): 1720-5.
 [http://dx.doi.org/10.1038/s41591-020-1050-x] [PMID: 32929265]

[60]
Chinnadurai R, Copland IB, Garcia MA, et al. Cryopreserved mesenchymal stromal cells are susceptible to T-Cell mediated apoptosis which is partly rescued by IFNγ licensing. Stem Cells  2016; 34(9): 2429-42.
 [http://dx.doi.org/10.1002/stem.2415] [PMID: 27299362]

[61]
Oja S, Kaartinen T, Ahti M, Korhonen M, Laitinen A, Nystedt J. The utilization of freezing steps in Mesenchymal Stromal Cell (MSC) manufacturing: Potential impact on quality and cell functionality attributes. Front Immunol  2019; 10: 1627.
 [http://dx.doi.org/10.3389/fimmu.2019.01627] [PMID: 31379832]

[62]
Moll G, Geißler S, Catar R, et al. Cryopreserved or fresh mesenchymal stromal cells: Only a matter of taste or key to unleash the full clinical potential of MSC therapy? Adv Exp Med Biol  2016; 951: 77-98.
 [http://dx.doi.org/10.1007/978-3-319-45457-3_7] [PMID: 27837556]

[63]
Giri J, Galipeau J. Mesenchymal stromal cell therapeutic potency is dependent upon viability, route of delivery, and immune match. Blood Adv  2020; 4(9): 1987-97.
 [http://dx.doi.org/10.1182/bloodadvances.2020001711] [PMID: 32384543]

[64]
Wagner W, Horn P, Castoldi M, et al. Replicative senescence of mesenchymal stem cells: A continuous and organized process. PLoS One  2008; 3(5): e2213.
 [http://dx.doi.org/10.1371/journal.pone.0002213] [PMID: 18493317]

[65]
Kellum JA, Prowle JR. Paradigms of acute kidney injury in the intensive care setting. Nat Rev Nephrol  2018; 14(4): 217-30.
 [http://dx.doi.org/10.1038/nrneph.2017.184] [PMID: 29355173]

[66]
Ostermann M, Wu V, Sokolov D, Lumlertgul N. Definitions of acute renal dysfunction: An evolving clinical and biomarker paradigm. Curr Opin Crit Care  2021; 27(6): 553-9.
 [http://dx.doi.org/10.1097/MCC.0000000000000886] [PMID: 34535002]

[67]
Endre ZH, Mehta RL. Identification of acute kidney injury subphenotypes. Curr Opin Crit Care  2020; 26(6): 519-24.
 [http://dx.doi.org/10.1097/MCC.0000000000000772] [PMID: 33044239]

[68]
Fukumitsu M, Suzuki K. Mesenchymal stem/stromal cell therapy for pulmonary arterial hypertension: Comprehensive review of preclinical studies. J Cardiol  2019; 74(4): 304-12.
 [http://dx.doi.org/10.1016/j.jjcc.2019.04.006] [PMID: 31109735]

[69]
Preda MB, Lupan AM, Neculachi CA, et al. Evidence of mesenchymal stromal cell adaptation to local microenvironment following subcutaneous transplantation. J Cell Mol Med  2020; 24(18): 10889-97.
 [http://dx.doi.org/10.1111/jcmm.15717] [PMID: 32785979]

[70]
Chen Y, Hu Y, Zhou X, et al. Human umbilical cord-derived mesenchymal stem cells ameliorate psoriasis-like dermatitis by suppressing IL-17-producing γδ T cells. Cell Tissue Res  2022; 388(3): 549-63.
 [http://dx.doi.org/10.1007/s00441-022-03616-x] [PMID: 35347409]

Rights & Permissions Print Cite

Article Metrics

37

2

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/1574888X18666230206115046	Print ISSN 1574-888X
Publisher Name Bentham Science Publisher	Online ISSN 2212-3946

Current Stem Cell Research & Therapy

The Beneficial Effects of Mesenchymal Stem Cells in Acute Kidney Injury: A Narrative Review

Abstract

Graphical Abstract

Related Journals

Related Books